AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39014316 — intervention group
Group type: COMPARATOR
Intervention: Both groups measured pain scores at 12, 24, and 72 hours, and after one week
Number of subjects: 25
Study 39014369 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood
Number of subjects: 475
Study 39014430 — intervention group
Group type: COMPARATOR
Intervention: Standard weaning (SBT: 30-min PSV8 without PEEP followed by extubation with continuous suctioning)
Number of subjects: 1600
Study 39014430 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung-volume-preservation weaning (SBT: 30-min PSV8 + 5 cmH2O PEEP)
Number of subjects: 1600
Study 39014448 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of Morphine Hydrochloride (intravenous titration followed by subcutaneous relay)
Number of subjects: 22
Study 39014448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 39014463 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline therapy
Number of subjects: 59
Study 39014495 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized management of HFNC weaning guided by clinical decision support (CDS)
Number of subjects: 350
Study 39014495 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 350
Study 39014498 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrowband UVB (NB-UVB) combined with optimal topical therapy (OTT) for a minimum of 3 months and 8 to 16 weeks of NB-UVB
Number of subjects: 316
Study 39014498 — intervention group
Group type: COMPARATOR
Intervention: Optimal topical therapy (OTT) for 3 months
Number of subjects: 316
Study 39014512 — intervention group
Group type: EXPERIMENTAL
Intervention: Operator-independent continuous ultrasound monitoring (CUSdi)
Number of subjects: 49
Study 39014512 — intervention group
Group type: COMPARATOR
Intervention: Standard ultrasound measurement of EXdi and PCVdi
Number of subjects: 49
Study 39014512 — intervention group
Group type: COMPARATOR
Intervention: Standard ultrasound measurement of Pdi derived parameters
Number of subjects: 49
Study 39014551 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-TAVI Lung Ultrasound (LUS) assessment of pulmonary congestion (PC)
Number of subjects: 127
Study 39014551 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-TAVI Lung Ultrasound (LUS) assessment of pulmonary congestion (PC)
Number of subjects: 127
Study 39014551 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite endpoint of all-cause mortality, hospitalization for heart failure, and urgent medical visits for worsening dyspnoea at 12-month follow-up
Number of subjects: 127
Study 39014551 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-TAVI LUS-PC
Number of subjects: 127
Study 39014980 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary control engagement coping (e.g., problem-solving)
Number of subjects: 198
Study 39014980 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary control engagement coping (e.g., positive thinking)
Number of subjects: 198
Study 39014980 — intervention group
Group type: EXPERIMENTAL
Intervention: Disengagement coping (e.g., avoidance)
Number of subjects: 198
Study 39015065 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver Global Impression of Change in memory or daily activities
Number of subjects: 0
Study 39015176 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 101
Study 39015176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 39015189 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant tricuspid regurgitation (TR)
Number of subjects: 93
Study 39015189 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant TR
Number of subjects: 93
Study 39015189 — intervention group
Group type: EXPERIMENTAL
Intervention: NTpro-BNP
Number of subjects: 93
Study 39015350 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir/Lamivudine (DTG/3TC)
Number of subjects: 1234
Study 39015350 — intervention group
Group type: COMPARATOR
Intervention: Current Antiretroviral Regimen (CAR)
Number of subjects: 1234
Study 39015674 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow-Derived Mononuclear Cell Infusion into Renal Arteries
Number of subjects: 5
Study 39016010 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive SBP treatment
Number of subjects: 8442
Study 39016010 — intervention group
Group type: COMPARATOR
Intervention: Standard SBP treatment
Number of subjects: 8442
Study 39016024 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Cannabidiol
Number of subjects: 0
Study 39016024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39016053 — intervention group
Group type: EXPERIMENTAL
Intervention: Aumolertinib
Number of subjects: 106
Study 39016053 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib
Number of subjects: 106
Study 39016202 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized transcutaneous auricular vagus nerve stimulation
Number of subjects: 0
Study 39016202 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 39016261 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital care program (DCP)
Number of subjects: 5032
Study 39016317 — intervention group
Group type: EXPERIMENTAL
Intervention: Total breast reconstruction with autologous fat transfer (AFT)
Number of subjects: 0
Study 39016381 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal enhanced recovery pathway including preoperative and postoperative nonopioid analgesia with oral acetaminophen, gabapentin, and ketorolac.
Number of subjects: 89
Study 39016381 — intervention group
Group type: COMPARATOR
Intervention: Standard of care without multimodal analgesia.
Number of subjects: 89
Study 39016593 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular dihydrogen (H2) inhalation therapy (3.6% H2 and 96.4% N2)
Number of subjects: 12
Study 39016594 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid (LZD) treatment over 14 days
Number of subjects: 106
Study 39016623 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 200 mg every 2 weeks (q2w)
Number of subjects: 0
Study 39016623 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39016667 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message intervention (51 messages over 1000 days)
Number of subjects: 0
Study 39017661 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral microbiome in patients with oral cGVHD
Number of subjects: 80
Study 39017661 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and gut microbiota overlap
Number of subjects: 80
Study 39017661 — intervention group
Group type: COMPARATOR
Intervention: Longitudinal trajectories of oral and gut microbiomes
Number of subjects: 80
Study 39017667 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab plus tremelimumab (arm A)
Number of subjects: 72
Study 39017667 — intervention group
Group type: EXPERIMENTAL
Intervention: Adavosertib plus carboplatin (arm B)
Number of subjects: 72
Study 39017667 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceralasertib plus olaparib (arm C)
Number of subjects: 72
Study 39017697 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-PN
Number of subjects: 4640
Study 39017697 — intervention group
Group type: COMPARATOR
Intervention: Early-PN
Number of subjects: 4640
Study 39017806 — intervention group
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Number of subjects: 27
Study 39017806 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 27
Study 39018016 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozanimod 0.92 mg with concomitant SSRI/SNRI use in UC (n=67)
Number of subjects: 1158
Study 39018016 — intervention group
Group type: COMPARATOR
Intervention: Ozanimod 0.92 mg without concomitant SSRI/SNRI use in UC (n=1091)
Number of subjects: 1158
Study 39018016 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozanimod 0.92 mg with concomitant SSRI/SNRI use in RMS (n=274)
Number of subjects: 1158
Study 39018016 — intervention group
Group type: COMPARATOR
Intervention: Ozanimod 0.92 mg without concomitant SSRI/SNRI use in RMS (n=1982)
Number of subjects: 1158
Study 39018020 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitiligo
Number of subjects: 9460
Study 39018020 — intervention group
Group type: COMPARATOR
Intervention: Matched controls without vitiligo
Number of subjects: 9460
Study 39018024 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort study with pragmatic definition of compensated cirrhosis
Number of subjects: 0
Study 39018024 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitions of incident and recompensated ascites, overt hepatic encephalopathy, variceal hemorrhage, bleeding because of portal gastropathy, and hepatocellular carcinoma
Number of subjects: 0
Study 39018038 — intervention group
Group type: EXPERIMENTAL
Intervention: Cendakimab 720 mg, once weekly
Number of subjects: 221
Study 39018038 — intervention group
Group type: EXPERIMENTAL
Intervention: Cendakimab 720 mg, every 2 weeks
Number of subjects: 221
Study 39018038 — intervention group
Group type: EXPERIMENTAL
Intervention: Cendakimab 360 mg, every 2 weeks
Number of subjects: 221
Study 39018038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study 39018053 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-based nudge intervention targeting surgeons
Number of subjects: 387
Study 39018053 — intervention group
Group type: COMPARATOR
Intervention: Control period (pre-intervention)
Number of subjects: 387
Study 39018053 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention period (post-intervention)
Number of subjects: 387
Study 39018071 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-guided enhanced developmental intervention (usual care plus infant massage, enhanced visual stimulation, auditory stimulation, social interactions, and support for motor development)
Number of subjects: 100
Study 39018071 — intervention group
Group type: COMPARATOR
Intervention: Usual care (support for lactation, kangaroo care, and routine developmental therapies)
Number of subjects: 100
Study 39018103 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health data collection using Fitbit smartwatch and smartphone app for continuous collection of physical activity, sedentary behavior, sleep, and dietary data over 2 years, along with biometric assessments and questionnaires at 3 time points (baseline, 12-, and 24-month follow-up).
Number of subjects: 776
Study 39018119 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine pH-Ammonium Acid/Base Score
Number of subjects: 0
Study 39018119 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39018154 — intervention group
Group type: EXPERIMENTAL
Intervention: Selonsertib
Number of subjects: 0
Study 39018444 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantifiable spike antibody (Ab)
Number of subjects: 209
Study 39018444 — intervention group
Group type: EXPERIMENTAL
Intervention: Unquantifiable spike antibody (Ab)
Number of subjects: 209
Study 39018444 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantifiable nucleocapsid antigen (N Ag)
Number of subjects: 209
Study 39018444 — intervention group
Group type: EXPERIMENTAL
Intervention: Unquantifiable nucleocapsid antigen (N Ag)
Number of subjects: 209
Study 39018512 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab 20 mg every 4 weeks
Number of subjects: 1882
Study 39018512 — intervention group
Group type: COMPARATOR
Intervention: Teriflunomide 14 mg once daily
Number of subjects: 1882
Study 39018515 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored dose-dense chemotherapy
Number of subjects: 0
Study 39018515 — intervention group
Group type: COMPARATOR
Intervention: Standard adjuvant chemotherapy
Number of subjects: 0
Study 39018532 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day nirmatrelvir-ritonavir (300 mg of nirmatrelvir and 100 mg of ritonavir every 12 hours for 5 days)
Number of subjects: 2736
Study 39018532 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day nirmatrelvir-ritonavir (300 mg of nirmatrelvir and 100 mg of ritonavir every 12 hours for 10 days)
Number of subjects: 2736
Study 39018532 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 5 or 10 days)
Number of subjects: 2736
Study 39018532 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events across all groups
Number of subjects: 2736
Study 39018533 — intervention group
Group type: EXPERIMENTAL
Intervention: Efanesoctocog alfa (50 IU per kilogram of body weight) for 52 weeks
Number of subjects: 74
Study 39018531 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab
Number of subjects: 520
Study 39018531 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 520
Study 39018898 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release (SR) pregabalin (150 mg once daily)
Number of subjects: 130
Study 39018898 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release (IR) pregabalin (75 mg twice daily)
Number of subjects: 130
Study 39018898 — intervention group
Group type: COMPARATOR
Intervention: Comparison of SR pregabalin to IR pregabalin
Number of subjects: 130
Study 39019103 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 308
Study 39019103 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin
Number of subjects: 308
Study 39019119 — intervention group
Group type: EXPERIMENTAL
Intervention: Low BC (392 mg/day)
Number of subjects: 51
Study 39019119 — intervention group
Group type: EXPERIMENTAL
Intervention: High BC (784 mg/day)
Number of subjects: 51
Study 39019119 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 51
Study 39019150 — intervention group
Group type: EXPERIMENTAL
Intervention: Tebentafusp
Number of subjects: 378
Study 39019150 — intervention group
Group type: COMPARATOR
Intervention: Investigator's choice
Number of subjects: 378
Study 39019156 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer Network Counseling-txt (PNC-txt)
Number of subjects: 1078
Study 39019156 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 1078
Study 39019203 — intervention group
Group type: EXPERIMENTAL
Intervention: Stellarex Drug-Coated Balloon (2 µg/mm)
Number of subjects: 0
Study 39019203 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 39019496 — intervention group
Group type: EXPERIMENTAL
Intervention: HEARTS intervention
Number of subjects: 3935
Study 39019530 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 0
Study 39019530 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study 39019541 — intervention group
Group type: EXPERIMENTAL
Intervention: Cdyn-guided PEEP
Number of subjects: 60
Study 39019541 — intervention group
Group type: COMPARATOR
Intervention: Conventional PEEP
Number of subjects: 60
Study 39019622 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-consent incentive (postage stamps)
Number of subjects: 600258
Study 39019622 — intervention group
Group type: COMPARATOR
Intervention: Post-consent incentive (postage stamps)
Number of subjects: 600258
Study 39019639 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-based breast reconstruction
Number of subjects: 124
Study 39019639 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous breast reconstruction
Number of subjects: 124
Study 39019657 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterologous BNT162b2 + mRNA-1273 vaccination schedule
Number of subjects: 566
Study 39019657 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of mRNA-1273
Number of subjects: 566
Study 39019657 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraderal vaccination
Number of subjects: 566
Study 39019657 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted vaccination schedules after first booster vaccination
Number of subjects: 566
Study 39019657 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster vaccination (dose or brand unspecified)
Number of subjects: 566
Study 39019698 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized starting dose (ISD) regimen (200 mg QD for BW <77 kg or PLT <150,000/µL; 300 mg QD for BW ≥77 kg and PLT ≥150,000/µL)
Number of subjects: 1442
Study 39019698 — intervention group
Group type: COMPARATOR
Intervention: 300 mg fixed starting dose (FSD)
Number of subjects: 1442
Study 39019698 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher niraparib exposure (AUC)
Number of subjects: 1442
Study 39019875 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/day (D-50)
Number of subjects: 57
Study 39019875 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 100 mg/day (D-100)
Number of subjects: 57
Study 39019875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 39019979 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate, prednisone, and apalutamide (AAPA) for 8 weeks
Number of subjects: 186
Study 39020305 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenegermin t.i.d. (20 mcg/mL, 3 times daily)
Number of subjects: 247
Study 39020305 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenegermin b.i.d. (20 mcg/mL, 2 times daily)
Number of subjects: 247
Study 39020305 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (once daily or t.i.d.)
Number of subjects: 247
Study 39020307 — intervention group
Group type: EXPERIMENTAL
Intervention: STOPCOV intervention delivered by community health workers (CHWs) including face masks, sanitiser, bleach, and written information, followed by regular telephonic follow-up.
Number of subjects: 326
Study 39020307 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group).
Number of subjects: 326
Study 39020307 — intervention group
Group type: EXPERIMENTAL
Intervention: STOPCOV intervention.
Number of subjects: 326
Study 39020348 — intervention group
Group type: EXPERIMENTAL
Intervention: USM-IAM-based counselling
Number of subjects: 90
Study 39020348 — intervention group
Group type: COMPARATOR
Intervention: Standard counselling (SCG)
Number of subjects: 90
Study 39020405 — intervention group
Group type: EXPERIMENTAL
Intervention: Getting Better Bite by Bite (GBBB) intervention along with routine care
Number of subjects: 80
Study 39020405 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 80
Study 39020409 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (ET) for primary M3 occlusion
Number of subjects: 11
Study 39020446 — intervention group
Group type: EXPERIMENTAL
Intervention: One or two additional doses of COVID-19 vaccines 3 months apart
Number of subjects: 0
Study 39020503 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Bone Regeneration (GBR) treatment
Number of subjects: 66
Study 39020503 — intervention group
Group type: COMPARATOR
Intervention: Open Flap Debridement (OFD)
Number of subjects: 66
Study 39020518 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy and neoadjuvant chemotherapy in combination with sindilizumab
Number of subjects: 588
Study 39020518 — intervention group
Group type: COMPARATOR
Intervention: Short-course radiotherapy and neoadjuvant chemotherapy
Number of subjects: 588
Study 39021216 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative urine output (UO)
Number of subjects: 1184
Study 39021272 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined nivolumab and ipilimumab (n=25)
Number of subjects: 50
Study 39021272 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined nivolumab and ipilimumab with SBRT (n=25)
Number of subjects: 50
Study 39021478 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-cost kitchen with improved cookstove
Number of subjects: 1267
Study 39021478 — intervention group
Group type: COMPARATOR
Intervention: Traditional cookstoves (Control)
Number of subjects: 1267
Study 39021646 — intervention group
Group type: EXPERIMENTAL
Intervention: MAEva program (Mindfulness meditation, Acceptance, and Commitment to values program)
Number of subjects: 40
Study 39021751 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin
Number of subjects: 17
Study 39022168 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilonacept
Number of subjects: 74
Study 39022168 — intervention group
Group type: COMPARATOR
Intervention: Rilonacept interruption
Number of subjects: 74
Study 39022429 — intervention group
Group type: EXPERIMENTAL
Intervention: STOP group (40,000 IU subcutaneous EPO combined with 20 mg/kg intravenous ferric carboxymaltose if Hb < 13 g/dL the day before surgery or at ICU admission, and RBC transfusion if Hb ≤ 8 g/dL)
Number of subjects: 123
Study 39022429 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care without the bundle of care)
Number of subjects: 123
Study 39022429 — intervention group
Group type: EXPERIMENTAL
Intervention: STOP group
Number of subjects: 123
Study 39022429 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 123
Study 39022641 — intervention group
Group type: EXPERIMENTAL
Intervention: Fun For Wellness intervention
Number of subjects: 0
Study 39022700 — intervention group
Group type: EXPERIMENTAL
Intervention: MicroNET-covered stent
Number of subjects: 75
Study 39022700 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitor use as intraarterial (IA) bolus + intravenous (IV) infusion
Number of subjects: 75
Study 39022726 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS on ipsilesional primary motor cortex (M1)
Number of subjects: 120
Study 39022726 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS on ipsilesional ventral premotor cortex
Number of subjects: 120
Study 39022726 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS on contralesional M1
Number of subjects: 120
Study 39022726 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency rTMS on contralesional M1
Number of subjects: 120
Study 39022726 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions (high-frequency rTMS protocols)
Number of subjects: 120
Study 39022796 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg days 1-21 plus dexamethasone 40 mg days 1, 8, 15, 22, administered in 28-day cycles for a total of 12 cycles
Number of subjects: 23
Study 39022796 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide and dexamethasone regimen
Number of subjects: 23
Study 39022823 — intervention group
Group type: EXPERIMENTAL
Intervention: ILR screening
Number of subjects: 6004
Study 39022823 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 6004
Study 39022889 — intervention group
Group type: EXPERIMENTAL
Intervention: Horse Riding Simulator (HRS)
Number of subjects: 32